
According to WHO, there are a total of 155 new coronavirus vaccines under development worldwide, of which 23 have entered the clinical trial stage, at least 3 vaccines are currently in Phase 3 clinical trials, and at least 3 vaccines have completed phase 2 trials and are about to enter phase 3 (see the figure below for details).
Agency | Country | Progress |
Sinopharm/Wuhan Institute of Biological Products | China | Phase 3 |
Sinovac R&D | China | Phase 3 |
Oxford/AstraZeneca | UK | Phase 3 |
Sinopharm/Beijing Institute of Biological Products | China | Phase 2 |
Chinese Army's Medical Research Institute/CanSino Biologics | China | Phase 2 |
BioNTech/Pfizer | USA | Phase 2 |
Moderna | USA | Phase 2 |
A Phase 1 study typically studies a small number of people, normally 20-80 persons and focuses on whether a vaccine is safe and induces an immune response.
In Phase 2, the clinical study is expanded to several hundred persons and studies the safety, immunogenicity, recommended dosage, immunization schedule and methods of vaccination of candidate vaccinesA Phase 1 study typically studies a small number of people, normally 20-80 persons and focuses on whether a vaccine is safe and induces an immune response.
In Phase 3, the vaccine is given to thousands of people and the key goal is to evaluate the efficacy and again for safety.
The good news is all the above vaccines are now showing positive results.
The COVID-19 vaccine, as the most effective method to prevent infection with the COVID-19 virus, could be available by year end or early next year. But before getting vaccinated, keep social distancing, wear face mask and wash hands frequently can still be the best ways to protect the public from getting infected.
For government, finding (using rapid test kits) and tracking (using tracking app) could be much helpful in preventing the spread of COVID-19.

More information about Singclean IgG/IgM Test Kit, please find
-
singclean | 2020-07-29
2026 Singderm Global Academic Exchange Program First Stop Launches—— China-Thailand Aesthetic Injection Exchange& SymposiumFrom January 22nd to 23rd, Singderm successfully hosted the China-Thailand Aesthetic Injection Exchange& Symposium event, marking a significant step forward in promoting international collaboration within aesthetics. As a key strategic partner of Singderm in the Thai market, Pola Group invited a distinguished delegation of local experts, including: Dr. Rosalyn, Professor, Department of Anatomy, Dhurakij Pundit University, Bangkok Dr. Grace, Technical Director, Doctor Grace Clinic Dr. Jonny, Technical Director, Doctor Jonny Clinic The program was designed to deepen China-Thailand professional dialogue on injectable aesthetics and foster the integration and evolution of Eastern aesthetic concepts and techniques. -
singclean | 2020-07-29
Singclean to Showcase Aesthetic Manufacturing Excellence and Singderm Brand Strength at IMCAS 2026 -
singclean | 2020-07-29
Singclean Medical Strengthens Its Market Position at Russian Health Care Week 2025Singclean Medical successfully concluded its participation in Russian Health Care Week 2025, reinforcing its position as a comprehensive and reliable global supplier in the aesthetic and medical device industry. The exhibition served as a strategic platform for the company to showcase its diversified product portfolio, strong innovation capability, and growing influence in the Russian and neighboring markets.